Progress in Neurotherapeutics and Neuropsychopharmacology

by Edited by Jeffrey L. Cummings

• ISBN13: 9780521862530
• ISBN10: 0521862531
• Edition: 1st
• Format: Hardcover
• Copyright: 2006-05-08
• Publisher: Cambridge University Press

Summary

Published annually, volumes in this series provide readers with updates of recent clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of recent trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practising neurologists as well as clinical and translational neuroscientists.

Table of Contents

Preface	ix
Jeffrey L. Cummings
Contributors	xii
Introduction to neurotherapeutics and neuropsychopharmacology	1	(12)
Jeffrey L. Cummings
Rivastigmine in the treatment of dementia associated with Parkinson's disease: a randomized, double-blind, placebo-controlled study	13	(14)
Sibel Tekin
Roger Lane
Modafinil for the treatment of fatigue in multiple sclerosis	27	(10)
Bruno Stankoff
Catherine Lubetzki
Michel Clanet
Radiotherapy with concurrent and adjuvant temozolomide: a new standard of care for glioblastoma multiforme	37	(16)
Warren P. Mason
Rene O. Mirimanoff
Roger Stupp
Treating migraine attacks ASAP: concept and methodological issues	53	(10)
Natalie J. Wiendels
Michel D. Ferrari
Early phase trials of minocycline in amyotrophic lateral sclerosis	63	(16)
Paul H. Gordon
Joseph Choi
Dan H. Moore
Robert G. Miller
Creatine as a potential treatment for amyotrophic lateral sclerosis	79	(12)
Jeremy M. Shefner
AVP-923 as a novel treatment for pseudobulbar affect in ALS	91	(14)
Laura E. Pope
Liquid fluoxetine versus placebo for repetitive behaviors in childhood autism	105	(10)
Eric Hollander
Erika Swanson
Evdokia Anagnostou
Ann Phillips
William Chaplin
Stacey Wasserman
Testing multiple novel mechanisms for treating schizophrenia in a single trial	115	(6)
Herbert Y. Meltzer
Selegiline in the treatment of negative symptoms of schizophrenia	121	(12)
Allison Lin
J. Alexander Bodkin
Analysis of the cognitive enhancing effects of modafinil in schizophrenia	133	(16)
Danielle C. Turner
Barbara J. Sahakian
Efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder: results of a double-blind, six-week study, with a six-month, double-blind, continuation phase	149	(16)
George M. Simpson
Antony Loebel
Lewis Warrington
Ruoyong Yang
Subject index	165	(4)
Author index	169